Bendamustine

Drugbox
IUPAC_name = 4- [5- [Bis(2-chloroethyl)amino] -1-methylbenzimidazol-2-yl] butanoic acid

---

CAS_number = 16506-27-2
CAS_supplemental =
ATC_prefix =
ATC_suffix =
PubChem = 65628
DrugBank =
C = 16 | H = 21 | Cl = 2 | N = 3 | O = 2
molecular_weight = 358.262 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US = D
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US = Rx-only
routes_of_administration = Intravenous
licence_US =Treanda

Bendamustine (INN, "tradenames Ribomustin and Treanda"; also known as SDX-105) is a substance in the treatment of leukemia [cite journal |author=Kath R, Blumenstengel K, Fricke HJ, Höffken K |title=Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia |journal=J. Cancer Res. Clin. Oncol. |volume=127 |issue=1 |pages=48–54 |year=2001 |month=January |pmid=11206271 |doi= |url=http://link.springer.de/link/service/journals/00432/bibs/1127001/11270048.htm] . It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma. [cite journal |author=Bagchi S |title=Bendamustine for advanced sarcoma |journal=Lancet Oncol. |volume=8 |issue=8 |pages=674 |year=2007 |month=August |pmid=17726779 |doi= |url=]

History

Bendamustine received its first marketing approval in Germany, which is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited, which it is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries.

On March 20, 2008, Cephalon received approval from the United States Food and Drug Administration to market bendamustine in the US, where it is sold under the tradename Treanda. [cite web |url=http://www.cephalon.com/newsroom/news_reader.aspx?ID=1120688 |title=Cephalon press release - Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia |accessdate=2008-03-23 |format= |work= ] Bendamustine is the first drug approved for patients with CLL in the US since 2001.

References